Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, Krogan NJ. Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network. Cancer Discov 2018;8:1474-1489. [PMID: 30209081 PMCID: PMC6375299 DOI: 10.1158/2159-8290.cd-17-1018] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 03/22/2018] [Accepted: 08/17/2018] [Indexed: 02/07/2023]

For:	Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, Krogan NJ. Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network. Cancer Discov 2018;8:1474-1489. [PMID: 30209081 PMCID: PMC6375299 DOI: 10.1158/2159-8290.cd-17-1018] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 03/22/2018] [Accepted: 08/17/2018] [Indexed: 02/07/2023]

Number

Cited by Other Article(s)

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, Guo JZ, Swaney DL, Tummino TA, Huettenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Naing ZZC, Zhou Y, Peng S, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Shen W, Shi Y, Zhang Z, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Ramachandran R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Wankowicz SA, Bohn M, Sharp PP, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Roesch F, Vallet T, Meyer B, White KM, Miorin L, Rosenberg OS, Verba KA, Agard D, Ott M, Emerman M, Ruggero D, García-Sastre A, Jura N, von Zastrow M, Taunton J, Ashworth A, Schwartz O, Vignuzzi M, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor S, Fraser JS, Gross J, Sali A, Kortemme T, Beltrao P, Shokat K, Shoichet BK, Krogan NJ. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2020:2020.03.22.002386. [PMID: 32511329 PMCID: PMC7239059 DOI: 10.1101/2020.03.22.002386] [Citation(s) in RCA: 132] [Impact Index Per Article: 26.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]

Affiliation(s)

David E Gordon QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Gwendolyn M Jang QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Mehdi Bouhaddou QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Jiewei Xu QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Kirsten Obernier QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Matthew J O'Meara Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA
Jeffrey Z Guo QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Danielle L Swaney QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Tia A Tummino QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco
Ruth Huettenhain QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Robyn M Kaake QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Alicia L Richards QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Beril Tutuncuoglu QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Helene Foussard QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Jyoti Batra QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Kelsey Haas QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Maya Modak QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Minkyu Kim QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Paige Haas QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Benjamin J Polacco QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Hannes Braberg QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Jacqueline M Fabius QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Manon Eckhardt QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Margaret Soucheray QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Melanie J Bennett QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Merve Cakir QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Michael J McGregor QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Qiongyu Li QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Zun Zar Chi Naing QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Yuan Zhou QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Shiming Peng QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco
Ilsa T Kirby QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
James E Melnyk QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
John S Chorba QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
Kevin Lou QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
Shizhong A Dai QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
Wenqi Shen QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
Ying Shi QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
Ziyang Zhang QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
Inigo Barrio-Hernandez European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
Danish Memon European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
Claudia Hernandez-Armenta European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
Christopher J P Mathy QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA
Tina Perica QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Kala B Pilla QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Sai J Ganesan QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Daniel J Saltzberg QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Rakesh Ramachandran QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Xi Liu QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco
Sara B Rosenthal Center for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego
Lorenzo Calviello Department of Cell and Tissue Biology, University of California, San Francisco
Srivats Venkataramanan Department of Cell and Tissue Biology, University of California, San Francisco
Jose Liboy-Lugo Department of Cell and Tissue Biology, University of California, San Francisco
Yizhu Lin Department of Cell and Tissue Biology, University of California, San Francisco
Stephanie A Wankowicz QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA Biophysics Graduate Program, University of California, San Francisco Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Markus Bohn Department of Pharmaceutical Chemistry, University of California, San Francisco
Phillip P Sharp University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Raphael Trenker Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, 94158, USA
Janet M Young Division of Basic Sciences, Fred Hutchinson Cancer Research Center
Devin A Cavero J. David Gladstone Institutes, San Francisco, CA 94158, USA
Joseph Hiatt Medical Scientist Training Program, University of California, San Francisco, CA 94143, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA
Theodore L Roth Medical Scientist Training Program, University of California, San Francisco, CA 94143, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA
Ujjwal Rathore J. David Gladstone Institutes, San Francisco, CA 94158, USA
Advait Subramanian QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco
Julia Noack QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco
Mathieu Hubert Virus and Immunity Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
Ferdinand Roesch Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France
Thomas Vallet Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France
Björn Meyer Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France
Kris M White Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
Lisa Miorin Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
Oren S Rosenberg Department of Medicine, University of California San Francisco, San Francisco, CA, USA Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA Chan-Zuckerberg Biohub
Kliment A Verba QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco
David Agard QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA Biochemistry & Biophysics and Quantitative Biosciences Institute UCSF 600 16th St San Francisco, CA 94143
Melanie Ott J. David Gladstone Institutes, San Francisco, CA 94158, USA Department of Medicine, University of California San Francisco, San Francisco, CA, USA
Michael Emerman Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98103
Davide Ruggero Department of Urology, University of California, San Francisco, San Francisco, CA, USA Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Adolfo García-Sastre Department for Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY
Natalia Jura QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Mark von Zastrow QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA University of California San Francisco, Department of Psychiatry, San Francisco, CA, 94158, USA
Jack Taunton QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA
Alan Ashworth QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA
Olivier Schwartz Virus and Immunity Unit, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
Marco Vignuzzi Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France
Christophe d'Enfert Direction Scientifique, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris cedex 15, France
Shaeri Mukherjee QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA George William Hooper Foundation, Department of Microbiology and Immunology, UC San Francisco
Matt Jacobson Department of Pharmaceutical Chemistry, University of California, San Francisco
Harmit S Malik Division of Basic Sciences, Fred Hutchinson Cancer Research Center
Danica G Fujimori QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco
Trey Ideker Division of Genetics, Department of Medicine, University of California San Diego
Charles S Craik Department of Pharmaceutical Chemistry, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA
Stephen Floor Department of Cell and Tissue Biology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, 94158, USA
James S Fraser QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
John Gross QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco
Andrej Sali QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco
Tanja Kortemme QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco The UC Berkeley-UCSF Graduate Program in Bioengineering, University of California San Francisco, San Francisco, CA, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA
Pedro Beltrao European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK
Kevan Shokat QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA Howard Hughes Medical Institute
Brian K Shoichet QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA Department of Pharmaceutical Chemistry, University of California, San Francisco
Nevan J Krogan QBI COVID-19 Research Group (QCRG), San Francisco, CA, 94158, USA University of California San Francisco, Quantitative Biosciences Institute (QBI), San Francisco, CA, 94158, USA J. David Gladstone Institutes, San Francisco, CA 94158, USA University of California San Francisco, Department of Cellular and Molecular Pharmacology, San Francisco, CA, 94158, USA

Collapse

Pathak S, Wilczyński JR, Paradowska E. Factors in Oncogenesis: Viral Infections in Ovarian Cancer. Cancers (Basel) 2020;12:E561. [PMID: 32121320 PMCID: PMC7139377 DOI: 10.3390/cancers12030561] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2019] [Revised: 02/16/2020] [Accepted: 02/25/2020] [Indexed: 02/07/2023] Open

A Quantitative Genetic Interaction Map of HIV Infection. Mol Cell 2020;78:197-209.e7. [PMID: 32084337 DOI: 10.1016/j.molcel.2020.02.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 01/10/2020] [Accepted: 02/02/2020] [Indexed: 12/16/2022]

Guan Y, Wang G, Fails D, Nagarajan P, Ge Y. Unraveling cancer lineage drivers in squamous cell carcinomas. Pharmacol Ther 2020;206:107448. [PMID: 31836455 PMCID: PMC6995404 DOI: 10.1016/j.pharmthera.2019.107448] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Accepted: 12/03/2019] [Indexed: 12/12/2022]

Network of Interactions between ZIKA Virus Non-Structural Proteins and Human Host Proteins. Cells 2020;9:cells9010153. [PMID: 31936331 PMCID: PMC7016862 DOI: 10.3390/cells9010153] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Revised: 12/20/2019] [Accepted: 01/01/2020] [Indexed: 12/16/2022] Open

Zhao J, Zhan Q, Guo J, Liu M, Ruan Y, Zhu T, Han L, Li F. Phylogeny and polymorphism in the E6 and E7 of human papillomavirus: alpha-9 (HPV16, 31, 33, 52, 58), alpha-5 (HPV51), alpha-6 (HPV53, 66), alpha-7 (HPV18, 39, 59, 68) and alpha-10 (HPV6, 44) in women from Shanghai. Infect Agent Cancer 2019;14:38. [PMID: 31832087 PMCID: PMC6873513 DOI: 10.1186/s13027-019-0250-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 10/21/2019] [Indexed: 12/13/2022] Open

Tutuncuoglu B, Krogan NJ. Mapping genetic interactions in cancer: a road to rational combination therapies. Genome Med 2019;11:62. [PMID: 31640753 PMCID: PMC6805649 DOI: 10.1186/s13073-019-0680-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 10/16/2019] [Indexed: 01/08/2023] Open

Choonoo G, Blucher AS, Higgins S, Boardman M, Jeng S, Zheng C, Jacobs J, Anderson A, Chamberlin S, Evans N, Vigoda M, Cordier B, Tyner JW, Kulesz-Martin M, McWeeney SK, Laderas T. Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. PLoS One 2019;14:e0223639. [PMID: 31596908 PMCID: PMC6785123 DOI: 10.1371/journal.pone.0223639] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 09/25/2019] [Indexed: 11/18/2022] Open

Abstract

Head and neck squamous cell carcinoma (HNSCC) remains a morbid disease with poor prognosis and treatment that typically leaves patients with permanent damage to critical functions such as eating and talking. Currently only three targeted therapies are FDA approved for use in HNSCC, two of which are recently approved immunotherapies. In this work, we identify biological pathways involved with this disease that could potentially be targeted by current FDA approved cancer drugs and thereby expand the pool of potential therapies for use in HNSCC treatment. We analyzed 508 HNSCC patients with sequencing information from the Genomic Data Commons (GDC) database and assessed which biological pathways were significantly enriched for somatic mutations or copy number alterations. We then further classified pathways as either “light” or “dark” to the current reach of FDA-approved cancer drugs using the Cancer Targetome, a compendium of drug-target information. Light pathways are statistically enriched with somatic mutations (or copy number alterations) and contain one or more targets of current FDA-approved cancer drugs, while dark pathways are enriched with somatic mutations (or copy number alterations) but not currently targeted by FDA-approved cancer drugs. Our analyses indicated that approximately 35–38% of disease-specific pathways are in scope for repurposing of current cancer drugs. We further assess light and dark pathways for subgroups of patient tumor samples according to HPV status. The framework of light and dark pathways for HNSCC-enriched biological pathways allows us to better prioritize targeted therapies for further research in HNSCC based on the HNSCC genetic landscape and FDA-approved cancer drug information. We also highlight the importance in the identification of sub-pathways where targeting and cross targeting of other pathways may be most beneficial to predict positive or negative synergy with potential clinical significance. This framework is ideal for precision drug panel development, as well as identification of highly aberrant, untargeted candidates for future drug development.

Collapse

Affiliation(s)

Gabrielle Choonoo Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America
Aurora S. Blucher Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, United States of America * E-mail:
Samuel Higgins Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America
Mitzi Boardman Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America
Sophia Jeng Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Oregon Clinical and Translational Research Institute, Oregon Health & Science University, Portland, Oregon, United States of America
Christina Zheng Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America
James Jacobs Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America Pediatric Hematology and Oncology, OHSU Doernbecher Children’s Hospital, Portland, Oregon, United States of America
Ashley Anderson Department of Dermatology, Oregon Health & Science University, Portland, Oregon, United States of America
Steven Chamberlin Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America
Nathaniel Evans Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America
Myles Vigoda Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, United States of America Department of Dermatology, Oregon Health & Science University, Portland, Oregon, United States of America
Benjamin Cordier Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America
Jeffrey W. Tyner Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, United States of America Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, Oregon, United States of America
Molly Kulesz-Martin Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, United States of America Department of Dermatology, Oregon Health & Science University, Portland, Oregon, United States of America
Shannon K. McWeeney Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America Oregon Clinical and Translational Research Institute, Oregon Health & Science University, Portland, Oregon, United States of America
Ted Laderas Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America Division of Bioinformatics and Computational Biology, Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, United States of America

Collapse

Al-Eitan LN, Alghamdi MA, Tarkhan AH, Al-Qarqaz FA. Genome-Wide CpG Island Methylation Profiles of Cutaneous Skin with and without HPV Infection. Int J Mol Sci 2019;20:E4822. [PMID: 31569353 PMCID: PMC6801420 DOI: 10.3390/ijms20194822] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Revised: 09/13/2019] [Accepted: 09/16/2019] [Indexed: 12/15/2022] Open

Hüttenhain R, Xu J, Burton LA, Gordon DE, Hultquist JF, Johnson JR, Satkamp L, Hiatt J, Rhee DY, Baek K, Crosby DC, Frankel AD, Marson A, Harper JW, Alpi AF, Schulman BA, Gross JD, Krogan NJ. ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection. Cell Host Microbe 2019;26:86-99.e7. [PMID: 31253590 DOI: 10.1016/j.chom.2019.05.008] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 12/24/2018] [Accepted: 04/26/2019] [Indexed: 12/29/2022]

Affiliation(s)

Ruth Hüttenhain Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA.
Jiewei Xu Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA
Lily A Burton Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94143, USA
David E Gordon Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA
Judd F Hultquist Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Jeffrey R Johnson Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA
Laura Satkamp Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA
Joseph Hiatt Gladstone Institutes, San Francisco, CA 94158, USA; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA; Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA
David Y Rhee Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
Kheewoong Baek Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
David C Crosby Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94143, USA
Alan D Frankel Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94143, USA
Alexander Marson Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA; Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA 94720, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
J Wade Harper Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
Arno F Alpi Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
Brenda A Schulman Max Planck Institute of Biochemistry, 82152 Martinsried, Germany
John D Gross Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94143, USA
Nevan J Krogan Department of Cellular & Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, USA; Gladstone Institutes, San Francisco, CA 94158, USA; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA.

Collapse

Reid P, Marcu LG, Olver I, Moghaddasi L, Staudacher AH, Bezak E. Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. Radiother Oncol 2019;135:1-12. [PMID: 31015153 DOI: 10.1016/j.radonc.2019.02.016] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Revised: 02/17/2019] [Accepted: 02/18/2019] [Indexed: 12/15/2022]

Gillison ML, Akagi K, Xiao W, Jiang B, Pickard RKL, Li J, Swanson BJ, Agrawal AD, Zucker M, Stache-Crain B, Emde AK, Geiger HM, Robine N, Coombes KR, Symer DE. Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res 2018;29:1-17. [PMID: 30563911 PMCID: PMC6314162 DOI: 10.1101/gr.241141.118] [Citation(s) in RCA: 163] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Accepted: 11/30/2018] [Indexed: 12/15/2022]

Abstract

Human papillomavirus (HPV) is a necessary but insufficient cause of a subset of oral squamous cell carcinomas (OSCCs) that is increasing markedly in frequency. To identify contributory, secondary genetic alterations in these cancers, we used comprehensive genomics methods to compare 149 HPV-positive and 335 HPV-negative OSCC tumor/normal pairs. Different behavioral risk factors underlying the two OSCC types were reflected in distinctive genomic mutational signatures. In HPV-positive OSCCs, the signatures of APOBEC cytosine deaminase editing, associated with anti-viral immunity, were strongly linked to overall mutational burden. In contrast, in HPV-negative OSCCs, T>C substitutions in the sequence context 5'-ATN-3' correlated with tobacco exposure. Universal expression of HPV E6*1 and E7 oncogenes was a sine qua non of HPV-positive OSCCs. Significant enrichment of somatic mutations was confirmed or newly identified in PIK3CA, KMT2D, FGFR3, FBXW7, DDX3X, PTEN, TRAF3, RB1, CYLD, RIPK4, ZNF750, EP300, CASZ1, TAF5, RBL1, IFNGR1, and NFKBIA Of these, many affect host pathways already targeted by HPV oncoproteins, including the p53 and pRB pathways, or disrupt host defenses against viral infections, including interferon (IFN) and nuclear factor kappa B signaling. Frequent copy number changes were associated with concordant changes in gene expression. Chr 11q (including CCND1) and 14q (including DICER1 and AKT1) were recurrently lost in HPV-positive OSCCs, in contrast to their gains in HPV-negative OSCCs. High-ranking variant allele fractions implicated ZNF750, PIK3CA, and EP300 mutations as candidate driver events in HPV-positive cancers. We conclude that virus-host interactions cooperatively shape the unique genetic features of these cancers, distinguishing them from their HPV-negative counterparts.

Collapse

Shah PS, Link N, Jang GM, Sharp PP, Zhu T, Swaney DL, Johnson JR, Von Dollen J, Ramage HR, Satkamp L, Newton B, Hüttenhain R, Petit MJ, Baum T, Everitt A, Laufman O, Tassetto M, Shales M, Stevenson E, Iglesias GN, Shokat L, Tripathi S, Balasubramaniam V, Webb LG, Aguirre S, Willsey AJ, Garcia-Sastre A, Pollard KS, Cherry S, Gamarnik AV, Marazzi I, Taunton J, Fernandez-Sesma A, Bellen HJ, Andino R, Krogan NJ. Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis. Cell 2018;175:1931-1945.e18. [PMID: 30550790 PMCID: PMC6474419 DOI: 10.1016/j.cell.2018.11.028] [Citation(s) in RCA: 236] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 11/10/2018] [Accepted: 11/19/2018] [Indexed: 01/03/2023]

Affiliation(s)

Priya S Shah Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Nichole Link Department of Molecular and Human Genetics, and Program in Developmental Biology, Baylor College of Medicine, Houston, TX, USA; Jan and Dan Duncan Neurological Research Institute, Houston, TX, USA; Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX, USA
Gwendolyn M Jang Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Phillip P Sharp Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA
Tongtong Zhu Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Danielle L Swaney Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Jeffrey R Johnson Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
John Von Dollen Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Holly R Ramage Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA
Laura Satkamp Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Billy Newton Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Ruth Hüttenhain Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Marine J Petit Department of Chemical Engineering, Department of Microbiology and Molecular Genetics, University of California Davis, Davis, CA, USA
Tierney Baum Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
Amanda Everitt Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
Orly Laufman Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA
Michel Tassetto Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA
Michael Shales Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Erica Stevenson Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Gabriel N Iglesias Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Leila Shokat Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA
Shashank Tripathi Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Vinod Balasubramaniam Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia
Laurence G Webb Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Sebastian Aguirre Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
A Jeremy Willsey Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; Institute for Neurodegenerative Diseases, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA; Department of Psychiatry, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA
Adolfo Garcia-Sastre Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Katherine S Pollard Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, Institute for Human Genetics, and Institute for Computational Health Sciences, University of California San Francisco, San Francisco, CA, USA; Chan-Zuckerberg Biohub, San Francisco, CA, USA
Sara Cherry Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA
Andrea V Gamarnik Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina
Ivan Marazzi Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Jack Taunton Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA
Ana Fernandez-Sesma Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Hugo J Bellen Department of Molecular and Human Genetics, and Program in Developmental Biology, Baylor College of Medicine, Houston, TX, USA; Jan and Dan Duncan Neurological Research Institute, Houston, TX, USA; Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX, USA.
Raul Andino Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, USA.
Nevan J Krogan Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA; Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA.

Collapse

Basler CF, Krogan NJ, Leung DW, Amarasinghe GK. Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets. Antiviral Res 2018;162:90-100. [PMID: 30550800 DOI: 10.1016/j.antiviral.2018.12.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 12/05/2018] [Accepted: 12/08/2018] [Indexed: 01/24/2023]